NDA 019516 · Knoa Pharma
Ms Contin
Morphine Sulfate · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
May 29, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,053
400 Phase 3, 129 recruiting
FAERS reports
121,251
103,850 serious, 35,051 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MS CONTIN Addiction, Abuse, and Misuse Because the use of MS CONTIN exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warning and Precautions (5.1) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of MS CONTIN, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential. Instruct patients to swallow MS CONTIN tablets whole; crushing, chewing, or dissolving MS CONTIN tablets can cause rapid release and absorption of a potentially fatal dose of...
What it is approved for
From the label in effect Aug 14, 2026.
MS CONTIN is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2) ] , reserve opioid analgesics, including MS CONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. MS CONTIN is not indicated as an as-needed (prn) analgesic. MS CONTIN is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including MS CONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) MS CONTIN is not indicated as an as-needed (prn) analgesic. ( 1 )
Mechanism: Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 1987 Original approval · Type 3 - New Dosage Form · priority review Other
5 products under this application
- MS CONTIN · MORPHINE SULFATE 200MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
- MS CONTIN · MORPHINE SULFATE 15MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- MS CONTIN · MORPHINE SULFATE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- MS CONTIN · MORPHINE SULFATE 100MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
- MS CONTIN · MORPHINE SULFATE 60MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- Patient-controlled Intravenous Analgesia Combined With Different Opioid Receptors for Gastrointestinal SurgeryPivotal-lookingCompleted
Xijing HospitalAcademic, hospital or other
NCT05576675 · 4,342 participants · Start May 1, 2018 · Primary completion Mar 31, 2022
Drug: sufentanil + nalbuphine; Sufentanil and 1 more · For: Gastrointestinal Surgery
Sites: XIan, China
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02145468 · 3,503 participants · Start Jun 3, 2014 · Primary completion Dec 14, 2015
Drug: Losmapimod 7.5 mg twice daily; Placebo twice daily and 1 more · For: Acute Coronary Syndrome
Sites: Huntsville, Alabama; Cottonwood, Arizona; Tucson, Arizona · 341 sites in all
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataPivotal-lookingCompleted
Jennifer Holder-MurrayAcademic, hospital or other
NCT04606264 · 3,395 participants · Start May 15, 2023 · Primary completion Mar 21, 2025
Drug: Neuraxial Analgesia; Regional Block 1: Paravertebral and 6 more · For: Perioperative Optimization
Sites: Pittsburgh, Pennsylvania · 3 sites in all
- Stellate Ganglion Morphine Infiltration on Myocardial I/R InjuryPivotal-lookingRecruiting
The Second Hospital of Anhui Medical UniversityAcademic, hospital or other
NCT07023679 · 2,588 participants (planned) · Start Jun 24, 2025 · Primary completion Jun 20, 2029
Drug: Morphine; saline placebo · For: Acute Myocardial Infarction (AMI)
Sites: Hefei, China · 2 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06372145 · 2,500 participants (planned) · Start Apr 16, 2024 · Primary completion Apr 30, 2029
Drug: Tolebrutinib; Placebo and 1 more · For: Relapsing Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Progressive Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 352 sites in all
- A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02576717 · 2,494 participants · Start Oct 16, 2015 · Primary completion Jan 5, 2023
Drug: RPC1063 · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Fresno, California · 175 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence32,898
- overdose23,556
- pain21,727
- death17,487
- emotional distress16,960
- drug withdrawal syndrome13,755
- toxicity to various agents11,853
- drug hypersensitivity10,283
- nausea5,733
- dependence5,010
- drug ineffective4,972
- fatigue4,059
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,656 |
| 2005 | 1,527 |
| 2006 | 1,241 |
| 2007 | 791 |
| 2008 | 884 |
| 2009 | 959 |
| 2010 | 1,280 |
| 2011 | 1,568 |
| 2012 | 2,361 |
| 2013 | 1,882 |
| 2014 | 2,318 |
| 2015 | 3,026 |
| 2016 | 3,584 |
| 2017 | 4,918 |
| 2018 | 26,849 |
| 2019 | 4,813 |
| 2020 | 8,668 |
| 2021 | 20,582 |
| 2022 | 14,405 |
| 2023 | 8,462 |
| 2024 | 3,692 |
| 2025 | 3,483 |
| 2026 | 2,297 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ms Contin (Morphine Sulfate)
2024 spending
$716K
Beneficiaries
224
1,013 claims
Per beneficiary
$3,197
$8.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,922,907 |
| 2021 | $1,651,076 |
| 2022 | $1,320,832 |
| 2023 | $1,079,068 |
| 2024 | $716,132 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Hydromorphone Compared to Morphine for Postoperative Analgesia: A Systematic Review and Meta-analysis.
Li Y, Yue X, Liang S, et al. · Pain Physician 2024 · Systematic Review, Meta-Analysis
- Substance use and spine density: a systematic review and meta-analysis of preclinical studies.
Oliva HNP, Prudente TP, Nunes EJ, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
- Morphine in acute coronary syndrome: systematic review and meta-analysis.
Duarte GS, Nunes-Ferreira A, Rodrigues FB, et al. · BMJ Open 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Intrathecal Morphine for Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ciconini LE, Ramos WA, Fonseca ACL, et al. · Ann Card Anaesth 2024 · Systematic Review, Meta-Analysis
- The analgesic effects of novel fascial plane blocks compared with intrathecal morphine after Caesarean delivery: a systematic review and meta-analysis.
Hussain N, Brull R, Thaete L, et al. · Br J Anaesth 2025 · Comparative Study, Meta-Analysis
- Opioid Dependency and Myocardial Infarction: A Systematic Review and Meta-Analysis.
Rohani F, Rezayat AA, Zarifian A, et al. · Curr Rev Clin Exp Pharmacol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Knoa Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.